US 12,337,184 B2
Systems, devices, and methods for improving patient outcomes in implantable cardioverter defibrillators
Yanhui Li, Suzhou (CN); and Robert Joseph Gaskill, Edina, MN (US)
Assigned to North American EP Technology LLC, Edina, MN (US)
Filed by North American EP Technology LLC, Saint Paul, MN (US)
Filed on Dec. 5, 2023, as Appl. No. 18/529,544.
Claims priority of provisional application 63/533,062, filed on Aug. 16, 2023.
Prior Publication US 2025/0058125 A1, Feb. 20, 2025
Int. Cl. A61N 1/365 (2006.01); A61N 1/05 (2006.01); A61N 1/362 (2006.01); A61N 1/39 (2006.01)
CPC A61N 1/36585 (2013.01) [A61N 1/0563 (2013.01); A61N 1/3621 (2013.01); A61N 1/39622 (2017.08)] 8 Claims
OG exemplary drawing
 
1. A method for reducing undesired treatments provided by an implantable cardioverter defibrillator (ICD) implanted in a patient, the method comprising:
implanting, in an anterior mediastinum of the patient, a lead of the ICD configured for prolonged implantation, the lead comprising at least an electrical sensor, a pressure sensor, and a treatment element;
receiving a first signal from the electrical sensor, the electrical sensor configured to measure electrical signals radiating from a heart of the patient;
receiving a second signal from the pressure sensor, the pressure sensor configured to measure pressure changes in the anterior mediastinum due to a mechanical functioning of the heart;
determining a hemodynamic status of the heart based on data from the second signal representing pressure changes in the anterior mediastinum;
determining a cardiac status based at least in part on a correlation of data from the first signal and the hemodynamic status of the heart;
determining, based on the cardiac status, if an adverse health event is occurring; and
responsive to determining that the adverse health event is occurring, applying a treatment to the heart of the patient via the ICD and the treatment element of the lead.